Given the capability of modulating individual gene expression in tumor cells, RNA agents such as small interfering RNA (siRNA) and messenger RNA (mRNA) have demonstrated tremendous potential in revealing the functionality of specific gene alterations and enabling novel classes of therapies for cancer treatment. The effective systemic RNA delivery to tumors, however, remains a formidable challenge for the widespread application of RNA technologies in cancer research and therapy. In this project, we propose to (i) develop robust nanoparticle (NP) platforms for effective in vivo delivery of siRNA and mRNA to tumor tissue, and (ii) apply this technology to relevant cancer therapeutic targets for treating non-small cell lung cancer (NSCLC). In recent efforts, we have conceived and developed a new generation of lipid-polymer hybrid NPs with promising features for systemic siRNA delivery, including long blood circulation, high tumor accumulation, and impressive gene silencing efficacy. We have also successfully employed these hybrid NPs to explore a putative therapeutic target, Prohibitin1 (PHB1), in NSCLC and to deliver tumor suppressor-encoded mRNA to cancer cells, as evidenced by inhibition of tumor cell growth in vitro and following systemic delivery in vivo. In light of these extensive and encouraging preliminary results, we hypothesize that the new lipid-polymer hybrid NP-mediated systemic RNA delivery will become a useful platform for in vivo evaluation of cancer targets and for the development of novel RNA therapies for cancer treatment.
In Aim 1, we will systematically optimize, understand and evaluate specific parameters that have been shown to control gene silencing efficiency and in vivo properties (e.g., pharmacokinetics, biodistribution, and side effects) of the hybrid NPs.
In Aim 2, we propose to explore the mechanisms and pathways underlying the PHB1 silencing-induced anti-tumor effect, using the optimized siRNA NPs from Aim 1. The hybrid NPs for systemic delivery of anti-PHB1 siRNA will be extensively examined in multiple NSCLC xenograft and orthotopic models.
In Aim 3, we will expand and refine the new hybrid NPs to deliver mRNA coding for tumor suppressors relevant to NSCLC, including PTEN and LKB1. This mRNA delivery approach for cancer therapy will be systematically investigated in vitro and in NSCLC xenograft and genetically engineered mouse models. At the conclusion of this project, we expect that the convergence of innovative RNA delivery strategy and significant discoveries in tumor biology will further strengthen our arsenal of therapies against NSCLC and other aggressive cancers.

Public Health Relevance

Lung cancer is the leading cause of cancer-related death in both men and women in the United States, and the estimated new cases and deaths in 2014 are 224,210 and 159,260, respectively. In particular, the 5-year survival rate of non-small cell lung cancer that accounts for ~ 85% of lung cancer cases is very low at late stages (14% for stage IIIA, 5% for stage IIIB, and 1% for stage IV). This project aims to develop effective, nanotechnology-based delivery methods for RNA-derived therapies, which will allow silencing of cancer- promoting genes as well as introduction of cancer suppressing genes to potentially reduce tumor burden and enhance the survival rate of patients with advanced lung cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Kondapaka, Sudhir B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Xu, Xiaoding; Wu, Jun; Liu, Shuaishuai et al. (2018) Redox-Responsive Nanoparticle-Mediated Systemic RNAi for Effective Cancer Therapy. Small 14:e1802565
Liu, Yanlan; Ji, Xiaoyuan; Tong, Winnie W L et al. (2018) Engineering Multifunctional RNAi Nanomedicine To Concurrently Target Cancer Hallmarks for Combinatorial Therapy. Angew Chem Int Ed Engl 57:1510-1513
Ling, Xiang; Chen, Xing; Riddell, Imogen A et al. (2018) Glutathione-Scavenging Poly(disulfide amide) Nanoparticles for the Effective Delivery of Pt(IV) Prodrugs and Reversal of Cisplatin Resistance. Nano Lett 18:4618-4625
Ji, Xiaoyuan; Kong, Na; Wang, Junqing et al. (2018) A Novel Top-Down Synthesis of Ultrathin 2D Boron Nanosheets for Multimodal Imaging-Guided Cancer Therapy. Adv Mater :e1803031
Liu, Yanlan; Ai, Kelong; Ji, Xiaoyuan et al. (2017) Comprehensive Insights into the Multi-Antioxidative Mechanisms of Melanin Nanoparticles and Their Application To Protect Brain from Injury in Ischemic Stroke. J Am Chem Soc 139:856-862
Tao, Wei; Zhu, Xianbing; Yu, Xinghua et al. (2017) Black Phosphorus Nanosheets as a Robust Delivery Platform for Cancer Theranostics. Adv Mater 29:
Xu, Xiaoding; Saw, Phei Er; Tao, Wei et al. (2017) ROS-Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy. Adv Mater 29:
Xu, Xiaoding; Saw, Phei Er; Tao, Wei et al. (2017) Tumor Microenvironment-Responsive Multistaged Nanoplatform for Systemic RNAi and Cancer Therapy. Nano Lett 17:4427-4435
Shi, Jinjun; Kantoff, Philip W; Wooster, Richard et al. (2017) Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 17:20-37
Liu, Yanlan; Ji, Xiaoyuan; Liu, Jianhua et al. (2017) Tantalum Sulfide Nanosheets as a Theranostic Nanoplatform for Computed Tomography Imaging-Guided Combinatorial Chemo-Photothermal Therapy. Adv Funct Mater 27:

Showing the most recent 10 out of 17 publications